4-methyl-N'-[(2Z)-1,1,1-trifluoro-4-oxo-4-(thiophen-2-yl)butan-2-ylidene]-1,2,3-thiadiazole-5-carbohydrazide

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-methyl-N'-[(2Z)-1,1,1-trifluoro-4-oxo-4-(thiophen-2-yl)butan-2-ylidene]-1,2,3-thiadiazole-5-carbohydrazide
• 英文别名: 4-methyl-N-[(Z)-(1,1,1-trifluoro-4-oxo-4-thiophen-2-ylbutan-2-ylidene)amino]thiadiazole-5-carboxamide
• 化学式: C₁₂H₉F₃N₄O₂S₂
• 分子量: 362.4
• InChiKey: FHTDNCJICUTQPT-MFOYZWKCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  141
• 氢给体数：
  1
• 氢受体数：
  10

文献信息

• METHODS OF INHIBITING THE FORMATION OF AMYLOID-BETA DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS
  申请人：Look Gary Charles

  公开号：US20110098309A1

  公开（公告）日：2011-04-28

  Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers from amyloid β1-42 monomers using acylhydrazide compounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β1-42 oligomers using acylhydrazide compounds.

  本发明涉及使用酰肼化合物抑制、调节和/或调节可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体从淀粉样β1-42单体形成的方法。本发明还涉及使用酰肼化合物治疗患有与可溶性、球形、非纤维化、神经毒性淀粉样β1-42寡聚体形成有关的疾病的患者的方法。
• METHODS OF INHIBITING THE FORMATION OF AMYLOID-ß DIFFUSABLE LIGANDS USING A ACYLHYDRAZIDE COMPOUNDS
  申请人：Acumen Pharmaceuticals, Inc.

  公开号：EP2194975A2

  公开（公告）日：2010-06-16
• [EN] METHODS OF INHIBITING THE FORMATION OF AMYLOID-B DIFFUSABLE LIGANDS USING ACYLHYDRAZIDE COMPOUNDS<br/>[FR] PROCÉDÉS CONSISTANT À INHIBER LA FORMATION DE LIGANDS DIFFUSABLES D'AMYLOIDE-B UTILISANT DES COMPOSÉS D'ACYLHYDRAZIDE
  申请人：ACUMEN PHARMACEUTICALS INC

  公开号：WO2009009768A2

  公开（公告）日：2009-01-15

  Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers from amyloid ß1-42 monomers using acylhydrazidecompounds. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid ß1-42 oligomers using acylhydrazidecompounds.